H.C. Wainwright raised the firm’s price target on Benitec Biopharma (BNTC) to $35 from $28 and keeps a Buy rating on the shares. The company ...
Dr. Mates served as the Chairman, Chief Executive Officer, and Co-founder of Intra-Cellular Therapies, a mental health company, from June 2002 until it was acquired by Johnson & Johnson in ...
Citizens JMP raised the firm’s price target on Benitec Biopharma (BNTC) to $22 from $20 and keeps an Outperform rating on the shares. Benitec ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback